Establishment and Validation of a Rabbit Model for In Vivo Pharmacodynamic Screening of Tachykinin NK_2 Antagonists
スポンサーリンク
概要
- 論文の詳細を見る
- 2012-04-20
著者
-
Inatomi Nobuhiro
Pharmaceutical Research Division Takeda Chemical Industries Ltd.
-
Tanaka Takahiro
Department Of Molecular Toxicology School Of Pharmaceutical Sciences University Of Shizuoka
-
Tsukimi Yasuhiro
Inflammation Drug Discovery Unit Pharmaceutical Research Division Takeda Pharmaceutical Company Limi
-
Imanishi Akio
Exploratory Research Center Pharmaceutical Research Division Takeda Pharmaceutical Company Limited
-
Kawamoto Makiko
Exploratory Research Center Pharmaceutical Research Division Takeda Pharmaceutical Company Limited
-
Kamiguchi Hidenori
Pharmaceutical Research Division Takeda Pharmaceutical Company Limited
-
Fujioka Yasushi
Pharmaceutical Research Division Takeda Pharmaceutical Company Limited
-
Kawamoto Makiko
Pharmaceutical Research Division Takeda Pharmaceutical Company Limited
-
Yamaguchi Masashi
Pharmaceutical Research Division Takeda Pharmaceutical Company Limited
-
TANAKA Takahiro
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
-
MATSUMOTO OKANO
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
-
IMANISHI Akio
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
-
MIURA Kasei
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
-
NISHIKAWA Yoichi
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
-
TSUKIMI Yasuhiro
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
-
Matsumoto Okano
Pharmaceutical Research Division Takeda Pharmaceutical Company Limited
-
Nishikawa Yoichi
Pharmaceutical Research Division Takeda Pharmaceutical Company Limited
-
Imanishi Akio
Pharmaceutical Research Division Takeda Pharmaceutical Company Limited
-
Tsukimi Yasuhiro
Pharmaceutical Research Division Takeda Pharmaceutical Company Limited
-
Miura Kasei
Pharmaceutical Research Division Takeda Pharmaceutical Company Limited
-
Matsumoto-Okano Shiho
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Japan
-
Inatomi Nobuhiro
Pharmaceutical Res. Div. Takeda Pharmaceutical Co. Ltd. Jpn
-
Inatomi Nobuhiro
Pharmaceutical Research Division Takeda Pharmaceutical Company Limited
関連論文
- Microbial Conversion of EM574 and EM523, Gastrointestinal motor Stimulating Agents
- Bioactive Metabolites of EM574 and EM523, Erythromycin Derivatives Having Strong Gastrointestinal Motor Stimulating Activity
- Vagus-Dependent and Vagus-Independent Mechanisms of Action of the Erythromycin Derivative EM574 and Motilin in Dogs
- Studies on the Mechanism of Action of the Gastric H^+,K^+-ATPase Inhibitor SPI-447
- Novelty Stress Increases Fecal Pellet Output in Mongolian Gerbils : Effects of Several Drugs
- Bidirectional Regulation of Human Colonic Smooth Muscle Contractility by Tachykinin NK2 Receptors
- Inhibition of Gastric H^+,K^+-ATPase by 3-Amino-5-methyl-2-(2-methyl-3-thienyl)imidazo[1,2-a]thieno[3,2-c]pyridine, SPI-447
- Effects of NSAIDs on Bladder Function in Normal and Cystitis Rats : a Comparison Study of Aspirin, Indomethacin, and Ketoprofen
- Mechanism of Action by Which Aspirin Alleviates Detrusor Hyperactivity in Rats
- Recent Advances in Gastrointestinal Pathophysiology : Role of Heat Shock Proteins in Mucosal Defense and Ulcer Healing
- Super-induced gene expression of the N-methyl-D-aspartate receptor 2C subunit in chemical-induced hypertrophic liver in rats
- Bidirectional Regulation of Human Colonic Smooth Muscle Contractility by Tachykinin NK_2 Receptors
- Establishment and Validation of a Rabbit Model for In Vivo Pharmacodynamic Screening of Tachykinin NK_2 Antagonists
- Effects of TAK-480, a Novel Tachykinin NK2–Receptor Antagonist, on Visceral Hypersensitivity in Rabbits and Ricinoleic Acid–Induced Defecation in Guinea Pigs
- Effects of TAK-480, a Novel Tachykinin NK_2-Receptor Antagonist, on Visceral Hypersensitivity in Rabbits and Ricinoleic Acid-Induced Defecation in Guinea Pigs
- Comparison of the Motor-Stimulating Action of EM523, an Erythromycin Derivative, and Prostaglandin F2.ALPHA. in Conscious Dogs.